538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients

Схожие документы

• Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
  по: Hagins, D, et al.
  Опубликовано: (2018)
• Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
  по: Ping‐Feng Wu, et al.
  Опубликовано: (2024-12-01)
• 5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
  по: Lazzarin, A, et al.
  Опубликовано: (2010)
• Plasma and Intracellular Concentrations in HIV-infected Patients Requiring Hemodialysis Dosed with Tenofovir Disoproxil Fumarate and Emtricitabine: TDF and FTC in HD
  по: Slaven, James E., et al.
  Опубликовано: (2016)
• Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
  по: Wissam K. Kabbara, et al.
  Опубликовано: (2015-09-01)